Obesity influences the outcomes of anti-IgE (omalizumab) therapy of asthma

Clin Exp Allergy. 2020 Oct;50(10):1196-1199. doi: 10.1111/cea.13696. Epub 2020 Jul 13.

Chao Gu¹, Katherine Upchurch², James Mamaril-Davis¹, Matthew Wiest^{1

2}, Bobby Lanier³, Mark Millard⁴, Jacob Turner⁵, HyeMee Joo^{1

2}, SangKon Oh^{1

2}

¹ Department of Immunology, Mayo Clinic, Scottsdale, Arizona, USA.
² Institute for Biomedical Studies, Baylor University, Waco, Texas, USA.
³ North Texas Institute for Clinical Trials, Ft Worth, Texas, USA.
⁴ Martha Foster Lung Care Center, Baylor University Medical Center, Dallas, Texas, USA.
⁵ Department of Mathematics and Statistics, Stephen F. Austin State University, Nacogdoches, Texas, USA.

No abstract available

Keywords: asthma; biomarkers; body mass index; immunoglobulin E; obesity; omalizumab.

Publication types